Alkermes plc
ALKS
株式のランク
#2726
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
株価
$41.39
最終同期: 2026-10-16
時価総額
$6.94B
変化（1日）
3.22%
変化（1年）
36.78%
国
IE
取引 Alkermes plc (ALKS)
カテゴリー
Healthcare
Alkermes plc（ALKS）のEPS
June 2026 時点のEPS TTM: $0.40
Alkermes plcの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$0.40です。2023年末には、EPSは$2.14で、2022年のEPS$-0.97と増加でした。
Alkermes plcのEPS履歴（2000から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $0.40 | -81.98% |
| 2024 | $2.22 | 3.74% |
| 2023 | $2.14 | -320.62% |
| 2022 | $-0.97 | 223.33% |
| 2021 | $-0.30 | -57.14% |
| 2020 | $-0.70 | -44.00% |
| 2019 | $-1.25 | 38.89% |
| 2018 | $-0.90 | -12.62% |
| 2017 | $-1.03 | -25.36% |
| 2016 | $-1.38 | -9.21% |
| 2015 | $-1.52 | 623.81% |
| 2014 | $-0.21 | -210.53% |
| 2013 | $0.19 | 0.00% |
| 2012 | $0.19 | -119.19% |
| 2011 | $-0.99 | 106.25% |
| 2010 | $-0.48 | 14.29% |
| 2009 | $-0.42 | -130.66% |
| 2008 | $1.37 | -17.47% |
| 2007 | $1.66 | 1,560.00% |
| 2006 | $0.10 | 150.00% |
| 2005 | $0.04 | -104.82% |
| 2004 | $-0.83 | -33.60% |
| 2003 | $-1.25 | -26.47% |
| 2002 | $-1.70 | 77.08% |
| 2001 | $-0.96 | 123.26% |
| 2000 | $-0.43 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | 4,230.00% |
US
|
|
| $-7.98 | -2,095.00% |
US
|
|
| $-5.29 | -1,422.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 6,835.00% |
NL
|
